Ann Surg Oncol

1. BANSAL VV, Mitchell O, Bregio C, Witmer HDD, et al
   Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk.
   Ann Surg Oncol. 2024;31:3339-3349.
   

   >> Share

   
   
2. GRAUR A, Saenger JA, Mercaldo ND, Simon J, et al
   Multimodality Management of Thoracic Tumors: Initial Experience With a Multidisciplinary Thoracic Ablation Conference.
   Ann Surg Oncol. 2024;31:3426-3436.
   

   >> Share

   
   

   
   BMC Cancer

3. CHEN M, Li R, Kong Y, Shi L, et al
   Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a mu
   BMC Cancer. 2024;24:429.
   

   >> Share

   
   
4. LI H, Li L, Liu Y, Deng Y, et al
   Predictive value of CT and (18)F-FDG PET/CT features on spread through air space in lung adenocarcinoma.
   BMC Cancer. 2024;24:434.
   

   >> Share

   
   
5. JIANG H, Li B, Wu M, Wang Q, et al
   Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
   BMC Cancer. 2024;24:428.
   

   >> Share

   
   
6. ARIMURA K, Kammer M, Rahman SMJ, Sheau-Chiann C, et al
   Elucidating the role of EPPK1 in lung adenocarcinoma development.
   BMC Cancer. 2024;24:441.
   

   >> Share

   
   
7. YANG Y, Xu J, Wang W, Ma M, et al
   A nomogram based on the quantitative and qualitative features of CT imaging for the prediction of the invasiveness of ground glass nodules in lung adenocarcinoma.
   BMC Cancer. 2024;24:438.
   

   >> Share

   
   
8. ZHANG D, Liu H, Zhao F, Guo P, et al
   Exploring the relationship between Treg-mediated risk in COPD and lung cancer through Mendelian randomization analysis and scRNA-seq data integration.
   BMC Cancer. 2024;24:453.
   

   >> Share

   
   

   
   Br J Cancer

9. MATHIESON L, Koppensteiner L, Dorward DA, O'Connor RA, et al
   Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome.
   Br J Cancer. 2024 Apr 6. doi: 10.1038/s41416-024-02671.
   

   >> Share

   
   
10. LI C, Liu L, You R, Li Y, et al
    Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study.
    Br J Cancer. 2024 Apr 9. doi: 10.1038/s41416-024-02678.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

11. URYU K, Imamura Y, Shimoyama R, Mase T, et al
    Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
    Cancer Chemother Pharmacol. 2024 Apr 8. doi: 10.1007/s00280-024-04666.
    

    >> Share

    
    

    
    Cancer Lett

12. YOKOTA E, Iwai M, Yukawa T, Naomoto Y, et al
    Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
    Cancer Lett. 2024;588:216816.
    

    >> Share

    
    
13. MOON JW, Hong BJ, Kim SK, Park MS, et al
    Systematic identification of a synthetic lethal interaction in brain-metastatic lung adenocarcinoma.
    Cancer Lett. 2024;588:216781.
    

    >> Share

    
    
14. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
    Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
    Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
    

    >> Share

    
    

    
    Cancer Res

15. NAM A, Jain S, Wu C, Campos A, et al
    Integrin alphavbeta3 Upregulation in Response to Nutrient Stress Promotes Lung Cancer Cell Metabolic Plasticity.
    Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/0008-5472.CAN-23-2700.
    

    >> Share

    
    

    
    Cancer Sci

16. ALANAZI M, Weng T, McLeod L, Gearing LJ, et al
    Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
    Cancer Sci. 2024 Apr 9. doi: 10.1111/cas.16171.
    

    >> Share

    
    
17. MORISE M, Kato T, Matsumoto S, Inoue T, et al
    Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Cancer Sci. 2024;115:1296-1305.
    

    >> Share

    
    
18. MIZOTE Y, Inoue T, Akazawa T, Kunimasa K, et al
    Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.
    Cancer Sci. 2024;115:1114-1128.
    

    >> Share

    
    

    
    Clin Lung Cancer

19. MARMARELIS ME, Scholes DG, McGrath CM, Priore SF, et al
    Brief Report: Impact of Reflex Testing on Tissue-Based Molecular Genotyping in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2024 Mar 12:S1525-7304(24)00037.
    

    >> Share

    
    
20. GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al
    A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
    Clin Lung Cancer. 2024 Mar 15:S1525-7304(24)00038.
    

    >> Share

    
    

    
    Eur J Cardiothorac Surg

21. SAKURAI H, Goto Y, Yoh K, Takamochi K, et al
    Prognostic significance of ground-glass areas within tumors in non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2024 Apr 10:ezae158. doi: 10.1093.
    

    >> Share

    
    
22. UEDA T, Takamochi K, Fukui M, Ichikawa T, et al
    Significance of preoperative exercise oxygen desaturation in lung cancer with interstitial lung disease.
    Eur J Cardiothorac Surg. 2024 Apr 10:ezae142. doi: 10.1093.
    

    >> Share

    
    
23. CHEN T, Wen J, He Y, Zhong Y, et al
    Neoadjuvant chemoimmunotherapy confers survival advantage for patients undergoing sleeve lobectomy.
    Eur J Cardiothorac Surg. 2024;65:ezae125.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

24. LEVIN N, Killingberg KT, Halvorsen TO, Danielsen S, et al
    Evaluation of radiotherapy treatment plans in a randomized phase II trial comparing two schedules of twice-daily thoracic radiotherapy in limited stage small-cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2024 Apr 5:S0360-3016(24)00475.
    

    >> Share

    
    

    
    J Cancer Res Clin Oncol

25. WANG Y, Lyu D, Cheng C, Zhou T, et al
    Preoperative nomogram for predicting spread through air spaces in clinical-stage IA non-small cell lung cancer using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
    J Cancer Res Clin Oncol. 2024;150:185.
    

    >> Share

    
    
26. HONG S, Lee JH, Heo JY, Suh KJ, et al
    Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
    J Cancer Res Clin Oncol. 2024;150:186.
    

    >> Share

    
    
27. WU X, Zhao X, Zhou C, Wei N, et al
    Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:188.
    

    >> Share

    
    

    
    J Nucl Med

28. LIU Z, Mhlanga JC, Xia H, Siegel BA, et al
    Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data.
    J Nucl Med. 2024 Feb 15:jnumed.123.266018. doi: 10.2967/jnumed.123.266018.
    

    >> Share

    
    

    
    J Thorac Oncol

29. GRAY SG, Meirson T, Mutti L
    Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
    J Thorac Oncol. 2024;19:541-546.
    

    >> Share

    
    
30. SAIFO M, Alali M, Alhabeb H, Awak M, et al
    Lung Cancer in Syria.
    J Thorac Oncol. 2024;19:534-540.
    

    >> Share

    
    
31. SHOENBILL KA, Goldstein AO
    Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
    J Thorac Oncol. 2024;19:531-533.
    

    >> Share

    
    
32. ZHU Z, Chen H
    Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
    J Thorac Oncol. 2024;19:528-530.
    

    >> Share

    
    
33. LEE JB, Nagasaka M
    Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
    J Thorac Oncol. 2024;19:525-527.
    

    >> Share

    
    
34. LEONG TL, McWilliams A, Wright GM
    Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
    J Thorac Oncol. 2024;19:522-524.
    

    >> Share

    
    
35. DWYER LJ, Singhal N, Yu B, Kao S, et al
    Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
    J Thorac Oncol. 2024;19:650-652.
    

    >> Share

    
    
36. RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al
    Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database.
    J Thorac Oncol. 2024;19:626-635.
    

    >> Share

    
    
37. MCNAMEE N, Harvey C, Gray L, Khoo T, et al
    Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
    J Thorac Oncol. 2024;19:636-642.
    

    >> Share

    
    
38. NEL AE, Pavlisko EN, Roggli VL
    The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy.
    J Thorac Oncol. 2024;19:551-564.
    

    >> Share

    
    
39. SMESSEIM I, Baas P
    Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
    J Thorac Oncol. 2024;19:547-550.
    

    >> Share

    
    
40. CHIOU CC, Lai TY
    Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
    J Thorac Oncol. 2024;19:e1-e2.
    

    >> Share

    
    
41. CHANG CL, Lin KC, Chen WM, Shia BC, et al
    Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
    J Thorac Oncol. 2024;19:e2-e4.
    

    >> Share

    
    
42. SHUKLA V, Wang H, Varticovski L, Baek S, et al
    Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131.
    

    >> Share

    
    

    
    JAMA Oncol

43. RODRIGUES G, Higgins KA, Rimner A, Amini A, et al
    American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Apr 11. doi: 10.1001/jamaoncol.2024.0294.
    

    >> Share

    
    

    
    Lung Cancer

44. MALAPELLE U, Passiglia F, Pepe F, Pisapia P, et al
    The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database.
    Lung Cancer. 2024;191:107787.
    

    >> Share

    
    
45. TAVERNA JA, Hung CN, Williams M, Williams R, et al
    Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
    Lung Cancer. 2024;190:107533.
    

    >> Share

    
    
46. JUNG HA, Park B, Park S, Sun JM, et al
    Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
    Lung Cancer. 2024;190:107536.
    

    >> Share

    
    
47. HONG DS, Cappuzzo F, Chul Cho B, Dowlati A, et al
    Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
    Lung Cancer. 2024;190:107512.
    

    >> Share

    
    
48. PROVENCIO M, Cobo M, Rodriguez-Abreu D, Carcereny E, et al
    Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.
    Lung Cancer. 2024;190:107513.
    

    >> Share

    
    
49. SUN L, Handorf EA, Zhou Y, Borghaei H, et al
    Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
    Lung Cancer. 2024;190:107510.
    

    >> Share

    
    
50. SLATORE CG, Hooker ER, Shull S, Golden SE, et al
    Association of patient and health care organization factors with incidental nodule guidelines adherence: A multi-system observational study.
    Lung Cancer. 2024;190:107526.
    

    >> Share

    
    
51. DAMHUIS RAM, Dickhoff C, Bahce I, Senan S, et al
    Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
    Lung Cancer. 2024;190:107532.
    

    >> Share

    
    
52. PANG LL, Zhuang WT, Huang YH, Liao J, et al
    Uncommon de novo EGFR(T790M)-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.
    Lung Cancer. 2024;190:107528.
    

    >> Share

    
    
53. YU T, Zhou X, Li M
    Comment on: Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas.
    Lung Cancer. 2024;190:107534.
    

    >> Share

    
    

    
    N Engl J Med

54. PASSARO A, Peters S
    Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
    N Engl J Med. 2024;390:1325-1327.
    

    >> Share

    
    
55. WU YL, Dziadziuszko R, Ahn JS, Barlesi F, et al
    Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:1265-1276.
    

    >> Share

    
    
56. IZZEDINE H, Bouderlique E, Besse B
    Selpercatinib and Pseudo-Decreases in Kidney Function.
    N Engl J Med. 2024;390:1241-1243.
    

    >> Share

    
    

    
    Oncogene

57. WANG X, Li X, Niu L, Lv F, et al
    FAK-LINC01089 negative regulatory loop controls chemoresistance and progression of small cell lung cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03027.
    

    >> Share

    
    

    
    Oncologist

58. CHEN HW, Kuo YW, Chen CY, Chang CH, et al
    Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
    Oncologist. 2024;29:e498-e506.
    

    >> Share

    
    
59. ARRIOLA E, Jaal J, Edvardsen A, Silvoniemi M, et al
    Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer.
    Oncologist. 2024;29:e561-e569.
    

    >> Share

    
    

    
    PLoS One

60. TRIPLETTE M, Kross EK, Snidarich M, Shahrir S, et al
    An alternating-intervention pilot trial on the impact of an informational handout on patient-reported outcomes and follow-up after lung cancer screening.
    PLoS One. 2024;19:e0300352.
    

    >> Share

    
    
61. MAY T, Clement MS, Halait H, Kohlmann A, et al
    Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.
    PLoS One. 2024;19:e0295987.
    

    >> Share

    
    
62. ZHANG H, Cheng X, Guo W, Zheng C, et al
    Metastasis patterns and prognosis in young gastric cancer patients: A propensity score?matched SEER database analysis.
    PLoS One. 2024;19:e0301834.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share